Products
Fibatuzumab Biosimilar Monoclonal Antibody (EPHA3) for Research
Pre-Made Fibatuzumab biosimilar, Whole mAb, Anti-EPHA3 Antibody: Anti-EK4/ETK/ETK1/HEK/HEK4/TYRO4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Fibatuzumab is a humanised monoclonal antibody directed against the ephrin receptor A3 (EPHA3) , which is a receptor tyrosine kinase implicated in mediating nervous system development .
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-211-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Fibatuzumab biosimilar, Whole mAb, Anti-EPHA3 Antibody: Anti-EK4/ETK/ETK1/HEK/HEK4/TYRO4 therapeutic antibody |
| INN Name | Fibatuzumab |
| Target | EPHA3 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2017 |
| Companies | Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute |
| Conditions Approved | na |
| Conditions Active | Acute myeloid leukaemia;Myelodysplastic syndromes;Myelofibrosis;Glioblastoma |
| Conditions Discontinued | na |
| Development Tech | POTELLIGENT Technology;Humaneering Technology |
About target - EPHA3
1. Protein Ephrin type-A receptor 3
2. Gene EPHA3
3. Organism Homo sapiens (Human)
Function
Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Highly promiscuous for ephrin-A ligands it binds preferentially EFNA5. Upon activation by EFNA5 regulates cell-cell adhesion, cytoskeletal organization and cell migration. Plays a role in cardiac cells migration and differentiation and regulates the formation of the atrioventricular canal and septum during development probably through activation by EFNA1. Involved in the retinotectal mapping of neurons. May also control the segregation but not the guidance of motor and sensory axons during neuromuscular circuit development.
Catalytic activity
ATP + L-tyrosyl-[protein] = ADP + H+ + O-phospho-L-tyrosyl-[protein]
EC:2.7.10.1
Source: Rhea.
